open access publication

Article, 2024

Moderators of treatment effect of non-steroidal anti-inflammatory drugs for patients with (sub) acute low back pain: Protocol for a systematic review with individual participant data meta-analysis

Methodsx, ISSN 2215-0161, Volume 12, 10.1016/j.mex.2024.102713

Contributors

Fu Y. 0000-0001-9553-6518 (Corresponding author) [1] Madsen S.D. 0000-0002-1054-2327 [2] [3] Abdel-Shaheed C. 0000-0003-1258-5125 [4] de Zoete A. 0000-0002-1421-3862 [5] Chiarotto A. 0000-0003-2350-9945 [1] Koes B.W. 0000-0002-0450-9969 [1] [3]

Affiliations

  1. [1] Erasmus MC
  2. [NORA names: Netherlands; Europe, EU; OECD];
  3. [2] Chiropractic Knowledge Hub
  4. [NORA names: Miscellaneous; Denmark; Europe, EU; Nordic; OECD];
  5. [3] University of Southern Denmark
  6. [NORA names: SDU University of Southern Denmark; University; Denmark; Europe, EU; Nordic; OECD];
  7. [4] University of Sydney
  8. [NORA names: Australia; Oceania; OECD];
  9. [5] Vrije Universiteit Amsterdam
  10. [NORA names: Netherlands; Europe, EU; OECD]

Abstract

A Cochrane review found that non-steroidal anti-inflammatory drugs (NSAIDs) are slightly more effective than placebo on acute and subacute low back pain (LBP) outcomes (pain intensity, disability, and global improvement). Our objectives are: (1) to assess the overall treatment effect of NSAIDs in adults with acute and subacute LBP; (2) to identify the moderation of baseline patients’ characteristics on treatment effect. We will conduct a systematic search of RCTs on effectiveness of NSAIDs compared with placebo in adults with non-chronic LBP in Medline ALL, Embase, Cochrane Central Register of Controlled Trials*. We will screen the records after January 2020, and include eligible RCTs before January 2020 screened by the Cochrane review mentioned above. Our primary outcomes are pain intensity, disability, and health-related quality of life, secondary outcomes are adverse events. Our IPD dataset will consist of the information on each eligible trial characteristics and included variables according to a predefined coding scheme. We will assess risk-of-bias of included RCTs with the Cochrane Risk Of Bias (RoB)-2 assessment tool. We will perform power calculations with closed-form solutions and prioritize a one-stage approach for IPD-MA. For reporting the results, we will adhere to the PRISMA-IPD statement.

Keywords

Acute and subacute LBP, Effect modifiers, Efficacy, Individual patient data (IPD) meta-analysis, Non-steroidal anti-inflammatory drugs, Subgroups

Funders

  • China Scholarship Council

Data Provider: Elsevier